Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 50 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $20.88 million which beat the analyst consensus estimate of $9.55 million by 118.60 percent. This is a 857.18 percent increase over sales of $2.18 million the same period last year.